medigraphic.com
ISSN 1405-1699 (Print)
Órgano Oficial del Colegio Mexicano de Alergia, Asma e Inmunología Pediátrica y de la Asociación Latinoamericana de Pediatría

2003, Number 1

Next >>

Alerg Asma Inmunol Pediatr 2003; 12 (1)

Efficacy and safety of standarized pollen immunotherapy in the treatment of al‘lergic rhinitis: A meta-analysis of randomized controlled trials

Huerta-Lopez JG, Penagos-Paniagua M

Language: English
References: 55
Page: 4-10
PDF size: 130.09 Kb.


ABSTRACT

The efficacy of pollen immunotherapy in patients with allergic rhinitis (AR) has been confirmed in many controlled trials. Recent studies suggest that SIT influence the response of T lymphocytes with a shift away from a TH2 response (IL-4, IL-5) towards a Th1 response (IFN-g). Objective: To evaluate the efficacy and safety of SIT in the treatment of allergic rhinitis by a meta-analysis of randomized and controlled clinical trials, previously published. Methods: A search was made in the electronic bases. Only controlled and randomized clinical trials were included. The primary outcomes were symptoms severity, adverse effects frequency and rescue medication requirements. Results: Twenty two articles were identified and reviewed. Ten studies (45%) fulfilled the selection criteria. Studies were published from 1997 to 2002. All studies used standarized extracts and were administered by a subcutaneous injection. Six hundred fourteen patients with AR were analyzed. Three hundred sixteen patients received SIT and 288 either placebo or symptomatic treatment. All authors found their studies were effective and safe. AR symptoms were higher in control group compared with SIT group (215 ± 131 vs 100 ± 24, p <0.001). Increase in the associate medication was also demonstrated in control group compared with SIT group (OR = 1.97, 95%CI 1.12 to 3.47, p = 0.02). Adverse effects frequency was higher in SIT group (OR = 2.32, 95%CI 1.05 to 5.1, p = 0.05). Conclusions: The results of this analysis indicate that the specific immunotherapy is effective and safe in patients with allergic rhinitis. The studies in pediatric population must be extended to establish conducts in this population.


REFERENCES

  1. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383: 387-93.

  2. Adkinson NF Jr, Eggleston PA, Eney D, et al. A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med 1997; 336: 324-31.

  3. Arkwright PD, David TJ. Intradermal administration of a killed Mycobacterium vaccae suspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease. J Allergy Clin Immunol 2001; 107: 531-4.

  4. Arvidsson MA, Löwhagen O, Rak S. Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy. J Allergy Clin Immunol 2002; 109: 777-83.

  5. Bødtger U, Poulsen LK, Jacobi HH, Malling HJ. The safety and efficacy of subcutaneous birch pollen immunotherapy -a one-year-randomized, double-blind, placebo-controlled study. Allergy 2002; 57: 297-305.

  6. Bohle B, Orel L, Kraft D, Ebner C. Oligodeoxynucleotides Containing CpG Motifs Induce Low Levels of TNF-a in Human B Lymphocytes: Possible Adjuvants for Th1 Responses. J Immunol 2001; 166: 3743-3756.

  7. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases: a WHO position paper. J Allergy Clin Immunol 1998; 102: 558.

  8. Bradding P, Feather IH, Howarth PH, et al. Interleukin 4 is localized to and released by human mast cells. J Exp Med 1992; 176: 1381-6.

  9. Camporota L, Corkhill A, Long H, Lordan J, Stanciu L, Tuckwell N, et al. The effects of Mycobacterium vaccae on allergen-induced airway responses in atopic asthma. Eur Respir J 2003; 21: 287-93.

  10. Cappelleri JC, Ioannidis JP, Schmid CH, de Ferranti SD, Aubert M, Chalmers TC, et al. Large trials vs meta-analysis of smaller trials: How do their results compare? JAMA 1996; 276: 1332-8.

  11. Del Prete G, Maggi E, Parronchi P, et al. IL-4 is an essential factor for the IgE synthesis induced in vitro by human T cell clones and their supernatants. J Immunol 1988; 140: 4193-8.

  12. DerSimonian R, Livine RJ. Resolving discrepancies between a meta-analysis and a subsequent large controlled trial. JAMA 1999; 282: 664-70.

  13. Des Roches A, Paradis L, Knani J, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy 1996; 51: 430-3.

  14. Des Roches A, Paradis L, Menardo JL, Bouges S, Daures JP, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitization’s in children. J Allergy Clin Immunol 1997; 99: 450-3.

  15. Durham S, Walker S, Varga EM, Jacobson MR, O’brien F, Noble W, et Al. Long-Term Clinical Efficacy of Grass-Pollen Immunotherapy. N Engl J Med 1999; 341: 468-75.

  16. Durham SR, Till SJ. Immunologic changes associated with allergen immunotherapy. J Allergy Clin Immunol 1998; 102: 157-64.

  17. Durham SR, Ying S, Varney VA, et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996; 97: 1356-65.

  18. Ebner C, Siemann U, Bohle B, et al. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Ph1 p 1, a major grass pollen allergen. Clin Exp Allergy 1997; 27: 1007-15.

  19. Evidence-Based Medicine Working Group. Evidence-Based Medicine. A new Approach to Teaching the Practice of Medicine. JAMA 1992; 268: 2420-2425.

  20. Gleich GJ, Zimmermann EM, Henderson LL, Yunginger JW. Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study. J Allergy Clin Immunol 1982; 70: 261-71.

  21. Grammer LC, Shaughnessy MA, Suszko IM, Shaughnessy JJ, Patterson R. Persistence of efficacy after a brief course of polymerized ragweed allergen: a controlled study. J Allergy Clin Immunol 1984; 73: 484-9.

  22. Guyatt G, Sinclair J, Cook DJ, Glasziou P. Users’ Guides to the Medical Literature: XVI. How to Use a Treatment Recommendation. JAMA 1999; 281: 1836-1843.

  23. Hamid QA, Schotman E, Jacobson MR, Walker SM, Durham SR. Increases in IL-12 messenger RNA+ cells accompany inhibition of allergeninduced late skin responses after successful grass pollen immunotherapy. J Allergy Clin Immunol 1997; 99: 254-60.

  24. Imada M, Simons FE, Jay FT, Hayglass KT. Allergen-stimulated interleukin-4 and interferon-gamma production in primary culture: responses of subjects with allergic rhinitis and normal controls. Immunology 1995; 85: 373-80.

  25. Ioannidis JP, Cappelleri JC, Lau J. Meta-analyses and large randomized, controlled trials. N Engl J Med 1998; 338: 59-62.

  26. Jacobsen L, Nuchel Petersen B, Wihl JA, Lowenstein H, Ipsen H. Immunotherapy with partially purified and standardized tree pollen extracts. IV. Results from long-term (6-year) follow-up. Allergy 1997; 52: 914-20.

  27. Kay AB. Allergy and Allergic Diseases. N Engl J Med 2001; 344: 30-37.

  28. Klimek, L, Dormann D, Jarman ER, Cromwell O, Riechelmann Hs, Reske-Kunz A B. Short-term preseasonal birch pollen allergoid immunotherapy influences symptoms, specific nasal provocation and cytokine levels in nasal secretions, but not peripheral T-cell responses, in patients with allergic rhinitis. Clin Exp Allergy 1999; 29: 1326-1335.

  29. Klimekl, Wolf H, Mewes T, Dormann D, Reske-Kunz A, Schnitker J. The effect of short-term immunotherapy with molecular standarized grass and rye allergens on eosinophil cationic protein and tryptase in nasal secretions. J Allergy Clin Immunol 1999; 103: 47-53.

  30. Krieg AK, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374: 546.

  31. LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997; 337: 536-42.

  32. Leynadier F, Banoun L, Dollois B, Terrier P, Epstein M, Guinnepain Mt, Firon D, et al. Immunotherapy with a calcium phosphate-adsorbed five-grass-pollen extract in seasonal rhinoconjunctivitis: A double-blind, placebo-controlled study. Clin Exp Allergy 2001; 31: 988-996.

  33. Li JT, Lockey RF, Bernstein IL, Portnoy JM, Nicklas RA. Allergen immunotherapy: A practice parameter. Ann Allergy Asthma Immunol 2003; 90 (Suppl 1): 1-35.

  34. Lichtenstein LM, Ishizaka K, Norman PS, Sobotka AK, Hill BM. IgE antibody measurements in ragweed hay fever: relationship to clinical severity and the results of immunotherapy. J Clin Invest 1973; 52: 472-82.

  35. MacGlashan D Jr, White JM, Huang SK, Ono SJ, Schroeder JT, Lichtenstein LM. Secretion of IL-4 from human basophils: the relationship between IL-4 mRNA and protein in resting and stimulated basophils. J Immunol 1994; 152: 3006-16.

  36. Möller C, Dreborg S, Ferdousi HA, Halken S, Høst A, Jacobsen L, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-Study). J Allergy Clin Immunol 2002; 109: 251-6.

  37. Moqbel R, Ying S, Barkans J, et al. Identification of mRNA for interleukin-4 in human eosinophils with granule localization and release of the translated product. J Immunol 1995; 155: 4939-47.

  38. Mosbech H, Osterballe O. Does the effect of immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis. Allergy 1988; 43: 523-9.

  39. Naclerio RM, Proud D, Moylan B, et al. A double-blind study of the discontinuation of ragweed immunotherapy. J Allergy Clin Immunol 1997; 100: 293-300.

  40. Norman PS, Creticos PS, Marsh DG. Frequency of booster injections of allergoids. J Allergy Clin Immunol 1990; 85: 88-94.

  41. O’Garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 1998; 8: 275-83.

  42. Otsuka H, Mezawa A, Ohnishi M, Okubo K, Seki H, Okuda M. Changes in nasal metachromatic cells during allergen immunotherapy. Clin Exp Allergy 1991; 21: 115-9.

  43. Ozdemir C, Akkoc T, Bahceciler NN, Kucukercan D, Barlan IB, Basaran MM. Impact of Mycobacterium vaccae immunization on lung histopatology in a murine model of chronic asthma. Clin Exp Allergy 2003; 33: 266-70.

  44. Price JF, Warner JO, Hey EN, Turner MW, Soothill JF. A controlled trial of hyposensitization with adsorbed tyrosine Dermatophagoides pteronyssinus antigen in childhood asthma: in vivo aspects. Clin Allergy 1984; 14: 209-19.

  45. Rak S, Heinrich C, Jacobsen L, Scheynius A, Venge P. A double-blinded, comparative study of the effects of short preseason specific immunotherapy and topical steroids in patients with allergic rhinoconjunctivitis and asthma. J Allergy Clin Immunol 2001; 108: 921-8.

  46. Romagnani S. Biology of human Th1 and Th2 cells. J Clin Immunol 1995; 15: 121-9.

  47. Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994; 12: 227-57.

  48. Rosemberg W, Donald A. Evidence based medicine: an approach to clinical problem-solving. BMJ 1995; 310: 1122-6.

  49. Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of allergic rhintis: An analysis of randomized, prospective, single-or double-blind, placebo-controlled studies. Clin Ther 2000; 22: 342-50.

  50. Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 1993; 178: 2123-30.

  51. Till S, Durham S, Dickason R, et al. IL-13 production by allergenstimulated T cells is increased in allergic disease and associated with IL-5 but not IFN-gamma expression. Immunology 1997; 91: 53-7.

  52. Walker SM, Pajno GB, Torres M, Wilson DR, Durham SR. Grass pollen immunotherapy for seasonal rhinitis and asthma: A randomized, controlled trial. J Allergy Clin Immunol 2001; 107: 87-93.

  53. Wiedermann UB, Jahn-Schmid R, Bauer L, Renz H, Kraft D, Ebner C. Effects of adjuvants on the immune response to allergens in a murine model of allergen inhalation: Cholera toxin induces a Th1-like response to Bet v 1, the major birch pollen allergen. Clin Exp Immunol 1998; 111: 144.

  54. Wilson D, Nouri-Aria KT, Walker S, Pajno GB, O’brien F, Jacobson MR, et al. Grass pollen immunotherapy: Symptomatic improvement correlates with reductions in eosinphils and IL-5 mRNA expression in the nasal mucosa during the pollen season. J Allergy Clin Immunol 2001; 107: 971-6.

  55. Zenner HP, Baumgarten C, Rasp G, Kunkel G, Hauswald B, Ring J, et al. Short-term immunotherapy: A prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standarized grass and rye allergens in patients with grass pollen-induced allergic rhinitis. J Allergy Clin Immunol 1997; 100: 23-9.




2020     |     www.medigraphic.com